Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference

Monday, October 23, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. will present at the H.C. Wainwright 4th Annual Hepatitis B Virus Conference. The company is known for its advanced gene editing capabilities using the ARCUS platform, which allows for sophisticated gene edits. This presentation is an opportunity to highlight their innovative approaches in gene therapy.
Price reaction · baseline $8.907 (2023-10-20 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close
+0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is utilizing a novel proprietary ARCUS platform.
  • The company is focused on developing advanced gene editing therapies.
  • The upcoming conference provides a platform for showcasing innovations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Oct. 23, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

Frequently Asked Questions

What is the focus of Precision BioSciences?

Precision BioSciences focuses on advanced gene editing therapies using its ARCUS platform.

When is the H.C. Wainwright Conference?

The H.C. Wainwright 4th Annual Hepatitis B Virus Conference is scheduled for October 2023.

What technology does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for sophisticated gene edits.

What will be presented at the conference?

Precision BioSciences will showcase its innovations in gene editing therapies.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Hepatitis B gene editing ARCUS platform
Last updated: Oct 23, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →